Join our daily newsletter At The Bell to receive exclusive market insights
- Starpharma’s (SPL) VIRALEZE antiviral nasal spray has been successfully registered for sale in Europe and the U.K.
- Launch into these markets is on track and the product is expected to be available for online sales next month
- Additionally, Starpharma is in discussions with aged care, health care, travel providers and commercial partners to seek sales and marketing rights
- VIRALEZE contains SPL7013, which has been known to eradicate 99.9 per cent of SARS-CoV-2, the virus that causes COVID-19
- Essentially, it works by slowing down the infection of host cells and blocking the interaction between viral surface proteins and human cell receptor proteins
- Starpharma is up 9.09 per cent on the market this morning, with shares trading at $2.40
Starpharma’s (SPL) VIRALEZE antiviral nasal spray has been successfully registered for sale in Europe and the U.K.
Launch into these markets is on track and the product is expected to be available for online sales next month.
Additionally, Starpharma is in discussions with aged care, health care, travel providers and commercial partners to seek sales and marketing rights.
“We are delighted to have completed registration of VIRALEZE ahead of our original schedule and acknowledge the support of local and international specialist laboratories who have assisted Starpharma with the development of VIRALEZE,” CEO Dr Jackie Fairley said.
“We have already undertaken substantial launch preparations, including manufacturing in Europe, to ensure VIRALEZE is available to consumers and businesses as early as possible,” she added.
VIRALEZE is described as an easy-to-use antiviral nasal spray that contains SPL7013, which has been known to eradicate 99.9 per cent of SARS-CoV-2, the virus that causes COVID-19.
It works by slowing down the infection of host cells when applied to cells before and after exposure to the virus. From there, it blocks the interaction between viral surface proteins and human cell receptor proteins.
VIRALEZE has the potential to complement vaccines and personal protective equipment and further reduces risk by preventing the transmission of SARS-CoV-2.
“Starpharma is pleased to have successfully developed a product that has the potential to assist with the fight against the global COVID-19 pandemic,” Dr Jackie commented.
“The spray is easy to use and convenient – and works rapidly, without being absorbed into the bloodstream. If you are about to walk into the supermarket you would use it. The same is true for public transport, elevators, planes, bars and restaurants,” she concluded.
Starpharma is up 9.09 per cent on the market this morning, with shares trading at $2.40 at 10:31 am AEDT.
